Gritstone Oncology Inc
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for tre… Read more
Market Cap & Net Worth: Gritstone Oncology Inc (GRTS)
Gritstone Oncology Inc (NASDAQ:GRTS) has a market capitalization of $2.28 Million ($2.28 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #33913 globally and #11068 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Gritstone Oncology Inc's stock price $0.02 by its total outstanding shares 118109000 (118.11 Million).
Gritstone Oncology Inc Market Cap History: 2018 to 2024
Gritstone Oncology Inc's market capitalization history from 2018 to 2024. Data shows change from $1.82 Billion to $2.28 Million (-66.17% CAGR).
Gritstone Oncology Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Gritstone Oncology Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
181.02x
Gritstone Oncology Inc's market cap is 181.02 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $1.82 Billion | $1.19 Million | -$64.78 Million | 1537.31x | N/A |
| 2019 | $1.06 Billion | $4.37 Million | -$90.93 Million | 242.71x | N/A |
| 2020 | $465.35 Million | $4.04 Million | -$104.61 Million | 115.27x | N/A |
| 2021 | $1.52 Billion | $46.72 Million | -$74.95 Million | 32.51x | N/A |
| 2022 | $407.48 Million | $9.27 Million | -$113.13 Million | 43.96x | N/A |
| 2023 | $240.94 Million | $1.33 Million | -$138.49 Million | 181.02x | N/A |
Competitor Companies of GRTS by Market Capitalization
Companies near Gritstone Oncology Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Gritstone Oncology Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Gritstone Oncology Inc Historical Marketcap From 2018 to 2024
Between 2018 and today, Gritstone Oncology Inc's market cap moved from $1.82 Billion to $ 2.28 Million, with a yearly change of -66.17%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2024 | $2.28 Million | -99.05% |
| 2023 | $240.94 Million | -40.87% |
| 2022 | $407.48 Million | -73.17% |
| 2021 | $1.52 Billion | +226.40% |
| 2020 | $465.35 Million | -56.08% |
| 2019 | $1.06 Billion | -41.94% |
| 2018 | $1.82 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 29th, 2025 the market cap of Gritstone Oncology Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.28 Million USD |
| MoneyControl | $2.28 Million USD |
| MarketWatch | $2.28 Million USD |
| marketcap.company | $2.28 Million USD |
| Reuters | $2.28 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.